title: Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders.
abstract: BACKGROUND
  Idraparinux is a synthetic pentasaccharide that binds to antithrombin with high affinity. In view of its long half-life, it is suitable for once-a-week administration.
  
  
  OBJECTIVE
  To review the evidence favoring the use of idraparinux for the acute and long-term treatment of patients with venous thromboembolism (VTE) and for the prevention of thromboembolic events in patients with atrial fibrillation (AF).
  
  
  METHODS
  All preclinical and clinical studies carried out with the use of idraparinux were sought through electronic searches of MEDLINE from January 1, 1999 up to December 31, 2007.
  
  
  RESULTS
  The administration of idraparinux in subcutaneous fixed doses of 2.5 mg once weekly was found to be as effective and safe as conventional antithrombotic therapy in the initial treatment of patients with deep vein thrombosis, but less effective than standard therapy in the initial treatment of patients with primary pulmonary embolism. During a 6-month extension of thromboprophylaxis, idraparinux was effective in preventing recurrent VTE but was associated with an increased risk of bleeding versus placebo. Finally, in patients with AF the long-term treatment with idraparinux was as effective as vitamin K antagonists, but caused more bleeding.
  
  
  CONCLUSIONS
  In its current formulation, idraparinux can be recommended only for the initial treatment of patients with deep vein thrombosis. The bioequipotency of a biotinylated version of idraparinux (idrabiotaparinux), whose effects can be reversed by a neutralizing agent (avidin), is under investigation in the treatment of VTE at present, as is the use of lower doses in patients with AF.
authors.affiliation: Department of Medical and Surgical Sciences, Thromboembolism Unit, University of Padua, 35128 - Padua, Italy. paoloprandoni@tin.it
authors.forename: Paolo
authors.initials: P
authors.lastname: Prandoni
authors.forename: Daniela
authors.initials: D
authors.lastname: Tormene
authors.forename: Marica
authors.initials: M
authors.lastname: Perlati
authors.forename: Barbara
authors.initials: B
authors.lastname: Brandolin
authors.forename: Luca
authors.initials: L
authors.lastname: Spiezia
mesh_terms: D000818:Animals; D000991:Antithrombins / Q000378:metabolism; D001281:Atrial Fibrillation / Q000097:blood / Q000150:complications / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006207:Half-Life; D006801:Humans; D009844:Oligosaccharides / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D011485:Protein Binding; D013923:Thromboembolism / Q000097:blood / Q000188:drug therapy / Q000517:prevention & control
chemical_list: D000991:Antithrombins; D005343:Fibrinolytic Agents; D009844:Oligosaccharides; C479958:idraparinux